Abstract:
The aim of the research was to study the clinical and laboratory factors affecting the efficiency of combination therapy in colorectal cancer patients with metastatic liver lesion. Currently, there are different opinions regarding the treatment tactics and the use of targeted therapy in colorectal cancer (CRC) patients with liver metastases. 75 patients with CRC and metastatic liver lesion were included in the study. All patients received preoperative chemotherapy (PCT) according to the XELOX/FOLFOX4 regimens in combination with the targeted drugs bevacizumab and cetuximab. The combination of
PCT with the drug bevacizumab showed the best treatment results. The determination of individual clinical and laboratory risk factors that influenced the long-term treatment results of CRR patients with liver metastases was carried out, which may contribute to the individualization of the tactics of targeted therapy in this category of patients
